HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization is a phase 2, randomised interventional study registered as NCT07612007 by Mayo Clinic, with a registry enrolment figure of 80 participants, started 2026-09-01 and due to reach its primary completion in 2028-08-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Darizmetinib; Embolization Therapy; Hepatectomy; Magnetic Resonance Imaging; Placebo Administration; Positron Emission Tomography. Conditions listed: Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Resectable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8. Primary outcome: Future liver remnant size (FLR). Colorectal eligibility wording from the registry: "* REGISTRATION: Individuals with metachronous colorectal carcinoma liver metastases (CRCLM) after resection of the primary OR synchronous CRCLM with planned simultaneous resection of primary and metastatic disease". Sites: United States. No results are recorded here; the registry entry is the source.